No results for ‘’
Sandu Pharmaceuticals Ltd
₹37.01
(2.30%)
Tue, 15 Sept 2026, 03:44 am
Health Technology
Pharmaceuticals: Other
24.5KSandu Pharmaceuticals Enterprise Value (EV)
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 6.31 | 13.68 | 10.79 | 21.54 | 10.91 | 14.17 | 37.93 | 32.43 | 52.92 | 36.27 | 23.07 | 11.55 | 20.73 | 37.64 | 32.38 | 37.94 | 30.50 |
| Price to book ratio | 0.37 | 0.61 | 0.54 | 0.61 | 0.49 | 0.39 | 0.86 | 0.93 | 0.82 | 0.72 | 0.54 | 0.28 | 0.76 | 1.70 | 1.29 | 1.37 | 1.13 |
| Price to sales ratio | 0.38 | 0.61 | 0.41 | 0.38 | 0.29 | 0.20 | 0.41 | 0.45 | 0.52 | 0.41 | 0.31 | 0.17 | 0.39 | 0.91 | 0.75 | 0.82 | 0.70 |
| Price to cash flow ratio | 48.12 | 8.83 | 9.49 | 0 | 2.45 | 0 | 4.45 | 0 | 6.54 | 728.44 | 5.64 | 1.44 | 2.95 | 64.95 | 164.40 | 64.76 | 49.53 |
| Enterprise value | 8.13Cr | 11.1Cr | 10.08Cr | 13.49Cr | 13.36Cr | 15.5Cr | 23.87Cr | 28.15Cr | 30.35Cr | 28.3Cr | 20.82Cr | 8.02Cr | 11.01Cr | 55.65Cr | 46.94Cr | 54.3Cr | 45.15Cr |
| Enterprise value to EBITDA ratio | 5.09 | 7.12 | 6.03 | 7.30 | 6.88 | 7.24 | 10.59 | 9.80 | 16.27 | 11.42 | 9.78 | 5.50 | 5.12 | 19.35 | 18.88 | 23.65 | 16.33 |
| Debt to equity ratio | 0.19 | 0.19 | 0.17 | 0.24 | 0.48 | 0.55 | 0.69 | 0.61 | 0.39 | 0.34 | 0.21 | 0.04 | 0 | 0 | 0 | 0 | 0.01 |
| Return on equity % | 0 | 4.55 | 5.13 | 2.92 | 4.53 | 2.78 | 2.28 | 2.92 | -1.93 | 2.38 | 2.35 | 2.48 | 3.48 | 4.54 | 4.02 | 3.66 | 3.76 |
Sandu Pharmaceuticals Ltd Enterprise Value
The Sandu Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Sandu Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Sandu Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Sandu Pharmaceuticals Ltd (NSE: , BSE: 524703) is currently trading at ₹37.01, with a market capitalization of ₹35.76Cr. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Sandu Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Sandu Pharmaceuticals Ltd Enterprise Value Current Value
The current Sandu Pharmaceuticals Ltd Enterprise Value stands at 45.15Cr.
The Sandu Pharmaceuticals Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Sandu Pharmaceuticals Ltd Enterprise Value Historical Trend
The Sandu Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 45.15Cr
- 2023: 54.3Cr
- 2022: 46.94Cr
- 2021: 55.65Cr
- 2020: 11.01Cr
The decline in Sandu Pharmaceuticals Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Sandu Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Sandu Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Sandu Pharmaceuticals Ltd.
Sandu Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Sandu Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Sandu Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Sandu Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.